• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Mark Cuban Cost Plus Drug's Latest Collab is With Diathrive Health, Diabetes and Chronic Disease Management Solution Org

Article

Mark Cuban Cost Plus Drug, Cost Plus Drugs, company has recently partnered with Diathrive Health in the initiative to improve healthcare access, lowering costs and improving outcomes for those living with diabetes and other chronic diseases.

Mark Cuban Cost Plus Drug, Cost Plus Drugs, company has recently partnered with Diathrive Health in the initiative to improve healthcare access, lowering costs and improving outcomes for those living with diabetes and other chronic diseases.

Diathrive Health is a diabetes and chronic disease management solution organization. The company’s collaboration with Cost Plus Drugs can give consumers lower cost medications, diabetes testing supplies and more personalized, higher quality care so that they can achieve better health outcomes, according to a release by the Cuban drug company.

Diathrive assists its members to remove the financial, administrative and psychosocial barriers to managing a chronic condition. Members get unlimited diabetes testing supplies, clinical support from nurses who are Certified Diabetes Care and Education Specialists (CDCES) and access to the Diathrive Health app that enables users to self-educate and train themselves on how to manage their condition.

Alex Oshmyansky, CEO & founder of Mark Cuban Cost Plus Drug Company said the company was created to help solve the ongoing challenges of patients not being to afford medications and supplies and provide a way for patients to receive their treatments at an affordable price.

“We already offer transparent, low prices to cash-pay consumers and are excited to now be working with a company like Diathrive Health to further reduce the cost to patients, and to keep the patient record complete from both a clinical and financial perspective,” Oshmyansky said.

Michael Hennessy, founder and CEO of Diathrive Health, shared that chronic disease like diabetes are complex.

“The partnership with Cost Plus Drugs will give our customers another piece of the puzzle,” Hennessy said. “Diathrive Health is happy to work with a company and team who share our goals and values.”

Diathrive is just another piece to the Cost Plus Drugs puzzle, as they have partnered with multiple healthcare companies in the last few months. Some of these partnerships include pharmacy benefit managers Rightway, EmsanaRx and RxPreferred Benefits. Another partnership includes Capital Blue Cross. According to a tweet by SmithRx on February 22, they have also teamed up with Cost Plus Drugs, and by April members will be able to fill prescriptions at the discounted price.

Through Cost Plus Drugs and their collaborations, many customers seem to be enjoying the benefits. Mark Cuban has shared many of customer stories through Twitter.

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
© 2024 MJH Life Sciences

All rights reserved.